Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRXNASDAQ:EVLONASDAQ:KALVNASDAQ:RLMDNASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$2.90$2.12$1.50▼$2.95$37.66M0.838,835 shs10 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.04$9K0.7413,476 shs30 shsKALVKalVista Pharmaceuticals$11.22-0.8%$12.46$7.30▼$15.50$557.86M-0.01606,046 shs7,232 shsRLMDRelmada Therapeutics$0.66+9.9%$0.58$0.24▼$4.47$21.31M0.64967,218 shs1,981 shsSIGASiga Technologies$6.42-0.6%$6.07$4.95▼$12.83$459.36M0.93718,003 shs474,879 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals0.00%+3.94%+52.63%+87.10%-48.21%EVLOEvelo Biosciences0.00%0.00%+25.00%0.00%+150.00%KALVKalVista Pharmaceuticals-0.88%-5.20%-3.83%+1.43%-3.99%RLMDRelmada Therapeutics-1.59%-1.59%-16.67%+119.41%-79.99%SIGASiga Technologies+0.93%+5.33%+8.49%+18.98%-14.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEGRXEagle Pharmaceuticals2.2147 of 5 stars0.03.00.03.90.03.30.0EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals4.2188 of 5 stars3.61.00.04.43.12.50.6RLMDRelmada Therapeutics4.7583 of 5 stars3.15.00.04.41.94.21.3SIGASiga Technologies1.5234 of 5 stars0.01.00.00.02.10.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/AKALVKalVista Pharmaceuticals 3.13Buy$24.83121.33% UpsideRLMDRelmada Therapeutics 2.25Hold$5.00657.58% UpsideSIGASiga Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KALV, EVLO, RLMD, EGRX, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.15$7.25 per share0.40N/A∞EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.86 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ASIGASiga Technologies$138.72M3.31$0.83 per share7.72$3.02 per share2.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A7/7/2025 (Estimated)KALVKalVista Pharmaceuticals-$126.64M-$3.72N/AN/AN/AN/A-104.25%-78.69%7/10/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)SIGASiga Technologies$59.21M$0.679.605.14N/A40.30%25.21%22.05%7/30/2025 (Estimated)Latest KALV, EVLO, RLMD, EGRX, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83N/AN/AN/AN/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/A5/8/2025Q1 2025SIGASiga TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ALatest KALV, EVLO, RLMD, EGRX, and SIGA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASiga Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AKALVKalVista PharmaceuticalsN/A10.4410.44RLMDRelmada TherapeuticsN/A5.295.29SIGASiga TechnologiesN/A8.406.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%EVLOEvelo Biosciences0.31%KALVKalVista PharmaceuticalsN/ARLMDRelmada Therapeutics45.24%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%EVLOEvelo Biosciences1.02%KALVKalVista Pharmaceuticals10.50%RLMDRelmada Therapeutics20.70%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataEVLOEvelo Biosciences12018.98 million18.79 millionNo DataKALVKalVista Pharmaceuticals10049.72 million44.50 millionOptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableSIGASiga Technologies4071.44 million70.05 millionOptionableKALV, EVLO, RLMD, EGRX, and SIGA HeadlinesRecent News About These CompaniesWhy Siga Technologies Inc. (SIGA) Outpaced the Stock Market TodayJune 26, 2025 | zacks.comInvestors Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)June 26, 2025 | marketbeat.comNew nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactorsJune 25, 2025 | msn.comGeneral Atomics Achieves Another Milestone in Silicon Carbide Composite Nuclear Fuel Rod TechnologyJune 24, 2025 | indystar.comIHere's Why Siga Technologies Inc. (SIGA) Fell More Than Broader MarketJune 20, 2025 | zacks.comUndiscovered Gems In US Market Including SIGA Technologies And 2 Other Small CapsJune 17, 2025 | finance.yahoo.comBank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)June 16, 2025 | marketbeat.comWhy Siga Technologies Inc. (SIGA) Dipped More Than Broader Market TodayJune 13, 2025 | zacks.comSIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Harbor Capital Advisors Inc.June 13, 2025 | marketbeat.comTraders Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)June 12, 2025 | marketbeat.comSIGA Technologies, Inc. (NASDAQ:SIGA) Short Interest Down 12.5% in MayJune 4, 2025 | marketbeat.comWe Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster EarningsMay 16, 2025 | finance.yahoo.comUndiscovered Gems in the US Market for May 2025May 15, 2025 | finance.yahoo.comSIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)May 10, 2025 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSIGA Reports Financial Results for Three Months Ended March 31, 2025May 8, 2025 | globenewswire.comCalculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)May 2, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for InvestorsMay 1, 2025 | zacks.comSIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 ResultsMay 1, 2025 | globenewswire.comChiliz joins SIGA to help drive integrity in sportApril 30, 2025 | en.as.comEWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%April 29, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALV, EVLO, RLMD, EGRX, and SIGA Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$2.90 0.00 (0.00%) As of 06/30/2025Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 06/27/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.KalVista Pharmaceuticals NASDAQ:KALV$11.22 -0.09 (-0.80%) As of 09:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Relmada Therapeutics NASDAQ:RLMD$0.66 +0.06 (+9.95%) As of 09:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Siga Technologies NASDAQ:SIGA$6.42 -0.04 (-0.62%) As of 09:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Why McCormick Stock Could Soar After Durables Data Surprise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
